PARP inhibitor for triple-negative breast cancer
from Medscape Medical News
The investigational agent iniparib (Sanofi-Aventis) improved a number of clinical measures, including overall survival, in women with metastatic triple-negative breast cancer, according to final phase 2 study results. The results for iniparib, which inhibits PARP, or poly(adenosine-disposphate-ribose) polymerase, were presented earlier at the 2010 European Society for Medical Oncology Congress and have been published online in the New England Journal of Medicine.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063